为促进鹏华上证科创板芯片交易型开放式指数证券投资基金（以下简称KC芯片，基金代 码:588920）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月10日起为KC芯片提 供主做市服务。 2026年02月09日 上证公告（基金）【2026】299号 上海证券交易所 特此公告。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2026】300号 2026年02月09日 为促进西藏东财上证科创板50成份交易型开放式指数证券投资基金（以下简称科创东财，基金代 码:589850）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月10日起为科创东财提 供主做市服务。 上海证券交易所 特此公告。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2026】319号 特此公告。 上海证券交易所 2026年02月09日 为促进国泰上证科创板人工智能交易型开放式指数证券投资基金（以下简称科AI国泰，基金代 码:589110）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月10日起为科AI国泰 提供主做市服务。 ...

上海证券交易所 上证公告（基金）【2026】320号 为促进上证180金融交易型开放式指数证券投资基金（以下简称金融ETF，基金代码:510230）的市 场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业 务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月10日起为金融ETF提供主做市服 务。 特此公告。 2026年02月09日 ...

Core Viewpoint - The company, Shanghai Guotai Haitong Securities Asset Management Co., Ltd., will launch a fund conversion service for its publicly offered securities investment funds starting from February 9, 2026, to meet the investment needs of investors [1]. Group 1: Fund Conversion Service Details - The fund conversion service will be available for all publicly offered securities investment funds that meet the conversion business rules at the company's direct sales counter [1]. - Investors can convert their holdings in one fund to another fund managed by the same fund manager and sold by the same sales institution [1][2]. - The conversion service will be operational on trading days of the Shanghai and Shenzhen Stock Exchanges, except when the company announces a suspension of subscription or redemption [1]. Group 2: Applicable Funds - The conversion service applies to all publicly offered securities investment funds sold at the company's direct sales counter, excluding certain fund types such as fund of funds (FOF), money market funds, QDII funds, REITs, and specific personal pension fund shares [2]. Group 3: Conversion Rules - Both funds involved in the conversion must be managed by the same fund manager and registered with the same registration institution [4]. - The fund being converted out must be redeemable, while the fund being converted into must be available for subscription [4]. - The conversion price will be based on the net asset value of the funds on the day the conversion application is accepted [4]. - The conversion process follows a "first in, first out" principle regarding the registration dates of the fund shares [4]. Group 4: Conversion Process and Timing - The effective date for the conversion application is the day it is received, with confirmations typically occurring the next business day [5]. - Investors can check the status of their conversion from the second business day after the application [5]. - The holding period for the converted fund shares will restart from the confirmation date of the conversion [6]. Group 5: Conversion Fees - Conversion fees consist of the redemption fee from the fund being converted out and any difference in subscription fees between the two funds [9]. - The redemption fee will be charged according to the redemption fee rate of the fund being converted out [9]. - If the subscription fee for the fund being converted into is higher, the investor must pay the difference; otherwise, no additional fee will be charged [9]. Group 6: Important Notes - Single conversion applications must meet the minimum redemption and subscription amounts as specified in the fund's prospectus [10]. - Investors can withdraw their conversion requests before the end of the trading day on which they are submitted [8]. - The company reserves the right to adjust the conversion rules within the legal framework and fund contracts [11].

Group 1 - The core viewpoint of the news is that Ruihu Mould has disclosed its recent investor meeting, highlighting its ongoing projects and business performance in the automotive parts industry [1][2]. - Ruihu Mould's latest stock price is 34.77 yuan, with a total market capitalization of 7.278 billion yuan, and it ranks 10th in the automotive parts industry with a price-to-earnings ratio of 16.08 times, compared to the industry average of 56.51 times [1]. - The company detailed three fundraising projects aimed at enhancing its production capabilities, including the production of high-end passenger car moulds and smart manufacturing solutions [1]. Group 2 - In the smart robotics sector, Ruihu Mould's collaborative robots are primarily used in automotive manufacturing and general industrial applications, with plans to develop advanced mobile collaborative robots in partnership with Yaskawa Electric [2]. - The company maintains a high capacity utilization rate and has established stable relationships with core customers, with over 20% of its workforce dedicated to research and development [2]. - Ruihu Mould was founded on March 15, 2002, and as of January 30, 2026, it had 24,042 shareholders, with an average holding value of 302,700 yuan and an average shareholding of 8,700 shares [2].

Group 1 - The core viewpoint of the report is that Jingfeng Medical-B (02675) is rated as "Buy" with projected revenues of 4.32 billion, 8.11 billion, and 12.36 billion yuan for 2025-2027, respectively, and a target price of 73.20 yuan/79.57 HKD based on a 35X PS for 2026 [1] - Jingfeng Medical is a leader in the domestic surgical robot market, continuously innovating to drive technological advancements, having established a "three-in-one" surgical solution with multi-port, single-port, and natural orifice surgical robots [1] - The company has achieved significant milestones, being the first in China and the second globally to obtain regulatory approval for multiple types of surgical robots, with its MSP2000 system receiving CE certification in October 2025 [1] Group 2 - Since the commercialization of its multi-port surgical robot in December 2022, Jingfeng Medical has sold 20 units in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3 - In 2024, Jingfeng Medical successfully entered the overseas market, quickly securing 5 orders and establishing a global distribution network covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 units of core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Core Viewpoint - Cathay Securities initiates coverage on Precision Medical-B (02675) with a "Buy" rating, forecasting revenues of 432 million, 811 million, and 1.236 billion yuan for 2025-2027, respectively, and sets a target price of 73.20 yuan/79.57 HKD for 2026 based on a 35X PS ratio [1] Group 1: Company Overview - Precision Medical, founded in May 2017 in Shenzhen, is a leader in China's surgical robot sector, being the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - The company has developed a "three-in-one" surgical solution that includes multi-port, single-port, and remote systems, with its globally pioneering MSP2000 multi-port surgical robot system receiving CE certification in October 2025 [1] Group 2: Market Performance - Since the commercialization of its multi-port surgical robot in December 2022, Precision Medical sold 20 units in China in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3: International Expansion - In 2024, Precision Medical successfully entered the overseas market, securing 5 orders and establishing a global sales team covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Group 1 - The core business of the company is focused on the global commercial vehicle fleet management market, with an emphasis on AI-enabled smart hardware to meet customer needs and drive market growth [1] - The company reported a stock price of 72.87 yuan, with a market capitalization of 13.163 billion yuan, and a rolling P/E ratio of 38.22, ranking 10th in the computer equipment industry [1] - The company is actively pursuing opportunities in the Robobus sector, leveraging its experience with public transportation operators to integrate autonomous driving technology into existing products [2] Group 2 - The company has initiated a systematic layout for its Robobus business, including building autonomous driving test sites and expanding its R&D team [2] - The company’s production capacity is being enhanced with the establishment of a factory in Vietnam, which began operations in May 2023, with plans for a second phase starting in 2025 [2] - As of September 30, 2025, the company had 26,704 shareholders, an increase of 6,611, with an average holding value of 492,900 yuan [2]

Core Viewpoint - The integration of AI and brain-computer interfaces (BCIs) is accelerating the commercialization growth cycle, driven by technological iterations and policy support under the 14th Five-Year Plan [1][3]. Group 1: Technology Development - BCIs enable bidirectional information transmission, creating a collaborative pathway between humans and machines, with core functions including neural signal interpretation and external device control [2]. - Various technological routes are developing in parallel: non-invasive methods are currently mainstream due to their ease of use and safety, while semi-invasive and invasive methods offer advantages in risk-efficiency and high spatial resolution, respectively [2]. - The deep integration of AI with BCIs is a significant trend, enhancing signal decoding precision and efficiency through machine learning algorithms, leading to the evolution towards a "brain-machine intelligent community" [2]. Group 2: Market Dynamics - The global competition in the BCI industry is intensifying, with the US focusing on invasive technologies and China making breakthroughs in non-invasive and language decoding fields, while also catching up in invasive technologies [3]. - Domestic policies are supporting the BCI industry through the 14th Five-Year Plan, establishing a comprehensive support system that includes technological innovation, application scenarios, and medical insurance payment [3]. - Capital investment in the BCI sector is expected to see significant growth by 2025, with a notable increase in financing events and amounts, indicating a trend towards early-stage investment and a concentration of capital in leading enterprises [3]. Group 3: Application Scenarios - The healthcare sector is currently the most established application area for BCIs, with successful implementations in hearing impairment, tremor treatment, and motor rehabilitation, supported by a robust medical insurance payment system [4]. - Other application scenarios are rapidly expanding, including consumer markets targeting both disabled and healthy populations, and industrial applications focusing on high-risk, high-precision tasks transitioning from experimental validation to commercialization [4]. - Leading companies are building competitive advantages through comprehensive R&D, industry-academia collaboration, and multi-scenario layouts, creating differentiated strengths in non-invasive technology applications and AI integration [4].